OncoLux
1 known investors
OncoLux develops an optical theranostic system that gives surgeons intraoperative enhanced visualization of residual cancer and combines it with optical photodynamic therapy to treat remaining tumor tissue during surgery. The technology targets cancer surgery patients and clinicians in the medical device field.
Founders & leadership
AK
Alan KerseyinCEO
TM
Trevor MacDougallVP & COO
Investors · 1
Competitors · 4
by search overlapOncosenx7 shared keywordsOncoSenX is a late-stage pre-clinical cancer therapeutics company developing treatments that target solid tumors based on transcriptional activity. Its system pairs a patented Proteo-Lipid Vehicle (PLV) delivery agent with plasmid DNA payloads that induce apoptosis in cancer cells while sparing adjacent cells.
Exelixis6 shared keywordsExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.
Oncotelic Therapeutics6 shared keywordsOncotelic is a biopharmaceutical company developing oncology therapeutics, including immuno-oncology and nanomedicine approaches, and applying AI technology to drug development. It focuses on cancer treatments and other therapeutic areas.
StockTwits5 shared keywordsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
Companies competing with OncoLux for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does OncoLux do?
- OncoLux develops an optical theranostic system that gives surgeons intraoperative enhanced visualization of residual cancer and combines it with optical photodynamic therapy to treat remaining tumor tissue during surgery. The technology targets cancer surgery patients and clinicians in the medical device field.
- Who are OncoLux's investors?
- OncoLux's investors include Connecticut Innovations.